Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
Status unconfirmed · Phase 1 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus (RSV)
In brief
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Key facts
- Study ID
- NCT04909021
- Run by
- Meissa Vaccines, Inc.
- People needed
- 63
- Starts
- 2021-06-03
- Expected to finish
- 2023-10-01
- Last updated by the study team
- 2022-08-02
Who can join
Age: 1 and older, up to 3. Sex: any. Healthy volunteers: accepted.
Where it is running
- Benchmark Research — San Antonio, Texas, United States (enrolling)
- The Emory Children's Center — Atlanta, Georgia, United States (enrolling)
- MedPharmics — Metairie, Louisiana, United States (enrolling)
- Meridian Clinical Research — Omaha, Nebraska, United States (enrolling)
- Meridian Clinical Research — Binghamton, New York, United States (enrolling)
- MedPharmics — Phoenix, Arizona, United States (enrolling)
- Coastal Pediatric Research — Summerville, South Carolina, United States
- Paradigm Clinical Research — La Mesa, California, United States
- PanAmerican Clinical Research — Brownsville, Texas, United States
- Clinical Research Prime — Idaho Falls, Idaho, United States
- Aventiv Research — Columbus, Ohio, United States
- Meridian Clinical Research — Hastings, Nebraska, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.